ReviewDrugs2021
Ocular Toxicity of Targeted Anticancer Agents.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials.Investigational new drugs · 2023Trial
- Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.Drug safety · 2022Trial
- Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.International journal of clinical oncology · 2026Review
- Ocular Manifestations Associated with Hematologic Malignancies: Mechanisms, Diagnosis, and Management.Medical sciences (Basel, Switzerland) · 2026Review
- Bilateral Optic Neuritis Following Acute Glyphosate Inhalation: A Case Report.Neurology international · 2026Article
- Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review.Frontiers in immunology · 2026Review
- Overview of ocular toxicities associated with breast cancer therapies.Breast cancer research and treatment · 2025Review
- Combined retinal vein occlusion and retinal artery occlusion in a patient undergoing therapy for metastatic breast cancer: a case report.Journal of medical case reports · 2025Article
- Risk of Moderate to Severe Ocular Surface Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A Multicenter Cohort Study.Ophthalmology and therapy · 2025Article
- Risks of cataract surgery in solid and hematologic cancer survivors.Scientific reports · 2025Article
- Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies.The oncologist · 2024Review
- Validation of 11 added items of the outpatient version of the Utrecht Symptom Diary in patients receiving chemotherapy or targeted therapy.Journal of patient-reported outcomes · 2024Observational
- Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.Gynecologic oncology · 2024Review
- Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer medicine · 2024Review
- Ocular Surface Side Effects of Novel Anticancer Drugs.Cancers · 2024Review
- A Case Report of Fedratinib-Associated Uveitis.Cureus · 2024Article
- Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review.Frontiers in medicine · 2024Review
- Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis.Frontiers in immunology · 2024Article
- Low-grade serous ovarian cancer: expert consensus report on the state of the science.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Article
- Ocular Toxicity Profile of Targeted Cancer Therapy (TCT) at a US Tertiary Cancer Center.Cureus · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proliferation of targeted anticancer agents over the last two decades has revolutionized cancer treatment and improved survival in many previously refractory malignancies. However, many agents are associated with characteristic ophthalmic adverse effects. It is important that ophthalmologists recognize and maintain a high index of suspicion for these side effects in patients on targeted therapy. Most ophthalmic adverse effects can be treated with specific ocular therapy without discontinuation of cancer treatment, although it is important to be aware of the life-threatening and vision-threatening circumstances that would require therapy cessation in conjunction with the patient's oncologist. This review aims to summarize the ophthalmic adverse effects of targeted and hormonal anticancer agents and briefly describe their management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.